SAN FRANCISCO, CA--(Marketwired - January 28, 2016) - This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal.
The panelists who selected the 2016 Small-Cap Biotech Watchlist are George Zavoico of JonesTrading International Services, Mara Goldstein of Cantor Fitzgerald, Reni Benjamin of Raymond James, Raghuram (Ram) Selvaraju of Rodman and Renshaw, and Mike King of JMP Securities. They discussed their selections, as well as some of the forces they expect will drive the biotech and pharma markets in the new year, at the 2016 Biotech Showcase in San Francisco.
Reflecting on how biotech will shape up in 2016, most of the analysts were cautiously optimistic. The long-running biotech bull has shown some vulnerability, especially to macroeconomic forces that present headwinds to investment markets as a whole. But the sector's fundamentals, the analysts maintain, remain solid. Though Benjamin believes…
Continue reading this interview: The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
Asterias Biotherapeutics Inc. and CorMedix Inc. are sponsors of Streetwise Reports. FlexPharma paid to distribute. Reni Benjamin, Mara Goldstein, Michael King, Raghuram Selvaraju and George Zavoico had final approval of the content and are wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Benjamin, Ms. Goldstein, Mr. King, Mr. Selvaraju and Mr. Zavoico and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Carrie Beal Amaro